Aurobindo Pharma receives USFDA approval for Terbinafine HCL Tablet

New Delhi, July 3 (UNI) Drug maker Aurobindo Pharma Ltd today received the US Food and Drug Authority (FDA) for Terbinafine Hydrochloride tablets, on the first day after the expiry of the relevant patent.

The brand product has annual sales of about 654 million dollars in the US.

The drug, in the strength of 250 mg, is the generic equivalent of Novartis anti-fungal Lamisil Tablets.

UNI